<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827021</url>
  </required_header>
  <id_info>
    <org_study_id>FARM6X822T</org_study_id>
    <secondary_id>2008-006014-20</secondary_id>
    <nct_id>NCT00827021</nct_id>
  </id_info>
  <brief_title>The Clinical Evaluation of the Dose of Erythropoietins Trial</brief_title>
  <acronym>CEDOSE</acronym>
  <official_title>Effects of the Dose of Erythropoiesis Stimulating Agents on Cardiac-cerebrovascular Outcomes Quality of Life and Costs in Hemodialysis Patients. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giovanni FM Strippoli, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consorzio Mario Negri Sud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life
      in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are
      the most used treatment option.

      The purpose of this study is

        1. the evaluation of biochemical markers to determine the efficacy of individual prediction
           of ESAs therapy

        2. to determine the benefits and harms of different ESA doses therapeutic strategy for the
           management of anaemia of end stage kidney disease (ESKD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III pragmatic, randomized-controlled trial comparing different doses of ESAs in
      patients with renal anaemia.

      Study Sample:

      Total of 900 participants from Italy

      Background and Rationale:

      Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life
      in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are
      the most used treatment option. In observational studies higher haemoglobin (Hb) levels
      (around 10-13 g/dL) are associated with improved survival and quality of life compared to
      lower Hb levels (around 9 g/dL). Randomized studies have found that higher Hb targets,
      achieved and maintained with ESA, cause an increased risk of death, mainly due to adverse
      cardiac-cerebrovascular outcomes. It is possible that such effect is mediated by ESA dose.
      This hypothesis has not been formally tested and is the aim of the Clinical Evaluation of the
      DOSe of Erythropoietins (CEDOSE) trial.

      CEDOSE is the first independent multicentre trial exploring the benefits and harms of
      different ESA doses therapeutic strategy for the management of anaemia of end stage kidney
      disease (ESKD).

      Hypothesis:

      ESA resistance is associated with adverse vascular outcomes and poor quality of life in ESKD.

      The CEDOSE trial will evaluate the biochemical markers to determine the efficacy of
      individual prediction of ESAs therapy; moreover it will evaluate the benefits and harms of
      two fixed ESA doses and explore the role of two treatment strategies, one based on a low and
      one based on a high ESA dose.

      Interventions and Comparison:

      Patients will be randomized 1:1 to 4000 IU/week iv. versus 18000 IU/week iv. of epoetin alfa,
      beta or any other epoetin in equivalent doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TSAT (transferrin saturation), serum albumin, serum ferritin, serum transferrin, serum C reactive protein</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sudden death</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalizations due to acute coronary syndrome, transitory ischemic attacks, not planned coronary revascularization, peripheric revascularization.</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis of the cardiovascular access</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizures</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertensive events</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>at randomization and at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of all-cause mortality, non fatal myocardial infarction and stroke, hospitalizations due to acute coronary syndrome, transitory ischaemic attacks, not planned coronary revascularization procedures, peripheric revascularization procedures.</measure>
    <time_frame>after randomization at month 1, 2, 3, 6, 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">656</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>ESAs 1 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ESAs 2 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.</intervention_name>
    <description>4000 IU/week I.V. Until the end of the trial</description>
    <arm_group_label>ESAs 1 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.</intervention_name>
    <description>18000 IU/week I.V. Until the end of the trial</description>
    <arm_group_label>ESAs 2 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; = 18,

          -  End stage kidney disease and anemia

          -  Treatment with hemodialysis for renal replacement therapy

          -  no contraindications to erythropoietin stimulating agents (ESAs) or already treated
             with ESAs

        Exclusion Criteria:

          -  Patients with Hb levels &gt; 10 g/dl without ESAs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni FM Strippoli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione Mario Negri Sud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Beato Angelo</name>
      <address>
        <city>Acri</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Di Dio</name>
      <address>
        <city>Agrigento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Alghero ASL nÂ°1</name>
      <address>
        <city>Alghero</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Anzio e Nettuno</name>
      <address>
        <city>Anzio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bellaria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;A. Perrino&quot; Hospital</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Chieri ASL TO 5</name>
      <address>
        <city>Chieri</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Anna, San Fermo Battaglia</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Nuovo Sant'Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria OO.RR Foggia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. SUD - Formia ASL Latina</name>
      <address>
        <city>Formia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni di Dio di Gorizia</name>
      <address>
        <city>Gorizia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jesi (Carlo Urbani)</name>
      <address>
        <city>Jesi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Dialitico Diaverum, Ladispoli</name>
      <address>
        <city>Ladispoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Renzetti ASL Lanciano Vasto</name>
      <address>
        <city>Lanciano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera Ospedale Civile di Legnano</name>
      <address>
        <city>Legnano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fornaroli</name>
      <address>
        <city>Magenta</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Manduria</name>
      <address>
        <city>Manduria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Dialitico Diaverum Marsala</name>
      <address>
        <city>Marsala</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Valle D'Itria ASL TA</name>
      <address>
        <city>Martina Franca</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Nicosia</name>
      <address>
        <city>Nicosia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giacomo</name>
      <address>
        <city>Novi Ligure</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale G. Bernabeo</name>
      <address>
        <city>Ortona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnas Civico Di Cristina</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Emodialisi ausl Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria degli Angeli</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.P.I. Priverno</name>
      <address>
        <city>Priverno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova, Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Dialitico Diaverum, Riesi</name>
      <address>
        <city>Riesi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Barbara</name>
      <address>
        <city>Rogliano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Eugenio ASL RMC</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas, Rozzano</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Annunziata</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A.Landolfi</name>
      <address>
        <city>Solofra</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Alfredo Fiorini di Terracina</name>
      <address>
        <city>Terracina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera C.T.O./C.R.F./ M. Adelaide</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Pio da Pietrelcina</name>
      <address>
        <city>Vasto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Strippoli GF; Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE). Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials. 2010 Jun 9;11:70. doi: 10.1186/1745-6215-11-70.</citation>
    <PMID>20534124</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Consorzio Mario Negri Sud</investigator_affiliation>
    <investigator_full_name>Giovanni FM Strippoli, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

